H.C. Wainwright analyst Robert Burns raised the firm’s price target on Black Diamond Therapeutics to $12 from $11 and keeps a Buy rating on the shares following the Q4 report. The firm pulled its discounted cash flow valuation forward.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on BDTX:
- Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
- Black Diamond Therapeutics expects cash to fund requirements into 2Q25
- Black Diamond Therapeutics reports Q4 EPS (34c), consensus (47c)
- Black Diamond Therapeutics Announces Upcoming Presentation at AACR Annual Meeting 2024
- Black Diamond Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference
